Publicacións en colaboración con investigadores/as de University of California, San Diego (18)

2018

  1. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: A pooled analysis of the PALACE 1-3 studies

    RMD Open, Vol. 4, Núm. 1

2014

  1. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 6, pp. 1020-1026

2012

  1. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

  2. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

    Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2504-2517

  3. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196

2010

  1. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis

    Journal of International Medical Research, Vol. 38, Núm. 4, pp. 1213-1224

2009

  1. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety Results of a randomized, placebo-controlled study

    Arthritis and Rheumatism, Vol. 60, Núm. 4, pp. 976-986

1996

  1. ILA, a member of the human nerve growth factor/tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival

    Blood, Vol. 87, Núm. 7, pp. 2839-2845

1995

  1. CITOCINAS, CONDROCITOS Y ARTROSIS

    Revista Espanola de Reumatologia, Vol. 22, Núm. 1, pp. 27-31

  2. Chondrocyte apoptosis induced by nitric oxide

    American Journal of Pathology, Vol. 146, Núm. 1, pp. 75-85

  3. Cytokine regulation of chondrocyte functions

    Journal of Rheumatology

  4. Differentiation-dependent effects of IL-1 and TGF-β on human articular chondrocyte proliferation are related to inducible nitric oxide synthase expression

    Journal of Immunology, Vol. 154, Núm. 8, pp. 4018-4026

  5. Differentiation-dependent effects of IL-1 and TGF-β on human articular chondrocyte proliferation are related to inducible nitric oxide synthase expression

    Journal of Immunology, Vol. 154, Núm. 8, pp. 4027-4031

  6. Growth factor responsiveness of human articular chondrocytes in aging and development

    Arthritis & Rheumatism, Vol. 38, Núm. 7, pp. 960-968

  7. IL-1-induced nitric oxide inhibits chondrocyte proliferation via PGE2

    Experimental Cell Research, Vol. 218, Núm. 1, pp. 319-325

  8. Interleukin 1β suppresses transforming growth factor-induced inorganic pyrophosphate (PP(i)) production and expression of the PP(i)-generating enzyme PC-1 in human chondrocytes

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, Núm. 22, pp. 10364-10368

  9. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes

    Journal of Immunology, Vol. 155, Núm. 2, pp. 796-801

1994

  1. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis

    Journal of Neuroimmunology, Vol. 55, Núm. 1, pp. 107-115